Merck, J&J Head To Arbitration Over Remicade Deal
A dispute over whether Merck & Co. Inc. obtained rights to market two Johnson & Johnson arthritis drugs in its merger with Schering-Plough Corp. is slated to go before an arbitration...To view the full article, register now.
Already a subscriber? Click here to view full article